25,131 Shares in Lantheus Holdings, Inc. $LNTH Bought by Formula Growth Ltd.

Formula Growth Ltd. acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 25,131 shares of the medical equipment provider’s stock, valued at approximately $2,788,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. EverSource Wealth Advisors LLC raised its position in shares of Lantheus by 190.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after buying an additional 698 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of Lantheus by 37.4% in the 2nd quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock valued at $5,714,000 after acquiring an additional 19,008 shares during the last quarter. Baird Financial Group Inc. grew its position in Lantheus by 22.6% in the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock worth $222,000 after acquiring an additional 500 shares in the last quarter. Daiwa Securities Group Inc. grew its position in Lantheus by 88.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock worth $278,000 after acquiring an additional 1,591 shares in the last quarter. Finally, Osterweis Capital Management Inc. bought a new stake in Lantheus during the second quarter worth approximately $36,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Performance

Shares of NASDAQ:LNTH opened at $100.47 on Friday. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. Lantheus Holdings, Inc. has a 12 month low of $49.67 and a 12 month high of $111.86. The company has a market capitalization of $6.56 billion, a price-to-earnings ratio of 24.27 and a beta of -0.03. The firm’s 50-day moving average is $103.80 and its 200 day moving average is $91.51.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. During the same quarter last year, the firm earned $1.57 earnings per share. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. Research analysts predict that Lantheus Holdings, Inc. will post 4.48 EPS for the current year.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of recent research reports. CJS Securities downgraded Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Citizens Jmp reissued a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. William Blair set a $102.50 price target on Lantheus in a report on Monday, August 3rd. Finally, B. Riley Financial lowered Lantheus from a “buy” rating to a “hold” rating in a report on Monday, August 17th. Four equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Hold” and a consensus price target of $108.11.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.